This study explored the GHK-Cu copper peptide for its neuroprotective properties against Alzheimer’s Disease (AD). Researchers investigated whether intranasal delivery of GHK-Cu could enhance cognition and reduce hallmark neuropathological changes in 5xFAD transgenic mice, a well-established model of early-onset AD.

Over a 12-week period, male and female mice received intranasal GHK-Cu three times per week. Results demonstrated that GHK-Cu treatment improved memory performance, reduced amyloid plaque burden, and decreased neuroinflammatory activity compared with saline-treated controls. These outcomes position GHK-Cu peptide as a promising candidate for further preclinical evaluation in neurodegenerative research.

The GHK-Cu peptide (glycyl-L-histidyl-L-lysine bound to copper) is a naturally occurring complex known for its regenerative, antioxidant, and anti-inflammatory functions. It supports angiogenesis, tissue repair, and the modulation of transforming growth factor beta 1 (TGFβ1) signaling—a pathway linked to amyloid plaque formation and tau pathology.

Prior GHK-Cu studies showed it improves cognitive function in aged animals and counteracts oxidative stress relevant to AD pathogenesis. Because GHK-Cu copper peptide can be delivered intranasally, bypassing the restrictive blood-brain barrier, this route was selected as an efficient and non-invasive way to achieve central nervous system exposure.

The study used both male and female 5xFAD transgenic mice, aged four months at the onset of testing. Mice were divided into GHK-Cu–treated and saline-treated groups, along with wild-type controls. The GHK-Cu peptide was administered intranasally at a dose of 15 mg/kg three times weekly for three months.

Cognitive function was measured using the Y-Maze spontaneous alternation test, a reliable indicator of working memory. Neuropathological assessments included Congo red staining for amyloid plaques and MCP-1 immunohistochemistry to evaluate neuroinflammation.

Treatment with intranasal GHK-Cu significantly enhanced performance in the Y-Maze test. Female mice exhibited notable gains in spontaneous alternation scores at weeks 8 and 12, while males showed earlier improvement beginning at week 4. By the end of the study, the GHK-Cu–treated mice performed nearly at the level of wild-type controls, suggesting substantial restoration of working memory and executive function.

These behavioral outcomes align with prior GHK-Cu studies demonstrating improved cognition following peptide exposure.

Congo red staining revealed that GHK-Cu–treated transgenic mice displayed markedly fewer amyloid plaques in the frontal cortex, hippocampus, and thalamus compared with saline-treated counterparts. The plaques that did form were smaller, less dense, and less numerous.

These reductions indicate that intranasal GHK-Cu copper peptide not only mitigates amyloid accumulation but also potentially slows early neurodegenerative processes characteristic of AD pathology.

MCP-1 (monocyte chemoattractant protein-1) staining intensity—a biomarker of neuroinflammation—was significantly reduced in the frontal cortex and hippocampus of GHK-Cu–treated mice. Digital quantification confirmed lower optical density levels compared with saline-treated controls.

This indicates that GHK-Cu peptide effectively downregulated chemokine-related immune activation, supporting a more stable neuroinflammatory environment. The findings reinforce GHK-Cu’s multifaceted mechanism, including modulation of inflammatory and oxidative pathways.

Intranasal delivery allowed direct access to the brain through the olfactory and trigeminal pathways, bypassing the blood-brain barrier. This method increased peptide uptake efficiency while maintaining low systemic copper levels, minimizing toxicity risks.

Researchers emphasized that this non-invasive route could serve as a model for other neuroactive synthetic peptides, providing a foundation for future translational studies on neurodegenerative conditions.

This GHK-Cu latest research underscores a broad therapeutic potential via three mechanisms: antioxidant protection, anti-inflammatory regulation, and amyloid plaque reduction. By attenuating multiple pathological pathways simultaneously, GHK-Cu contrasts with traditional single-target AD drugs.

The study’s outcomes suggest that GHK-Cu copper peptide could hold translational value as a neuroprotective therapy, though further testing in aged or tau-based models is warranted. The authors also highlight the safety of repeated intranasal use and encourage long-term studies assessing neurodegeneration and synaptic health.

Intranasal GHK-Cu copper peptide treatment improved cognitive performance, reduced amyloid plaque deposition, and decreased MCP-1–mediated neuroinflammation in 5xFAD mice over a 12-week study. The evidence supports its viability as a neuroprotective and cognitive-enhancing agent for Alzheimer’s research.

This GHK-Cu latest research demonstrates that bypassing the blood-brain barrier through intranasal delivery may represent a promising strategy for peptide-based therapies aimed at neurodegeneration.